Valuation: Semler Scientific, Inc.

Market Cap 232M 203M 190M 174M 326M 22.16B 326M 2.28B 882M 11.32B 870M 851M 36.48B P/E 2023
16.8x
P/E 2024 10.5x
Enterprise Value 217M 190M 178M 163M 305M 20.74B 305M 2.14B 825M 10.59B 815M 797M 34.14B EV / Sales 2023
3.53x
EV / Sales 2024 8.63x
Free-Float
97.04%
Yield 2023 *
-
Yield 2024 -
1 day-4.87%
Current year+32.96%
Current year 15.45
Extreme 15.45
24.19
1 year 14.88
Extreme 14.885
34
3 years 14.88
Extreme 14.885
81.56
5 years 14.88
Extreme 14.885
153.21
10 years 1.28
Extreme 1.28
153.21
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - 2022-11-30
Corporate Secretary 45 2026-01-15
Director TitleAgeSince
Director/Board Member 41 2026-01-15
Date Insider Type Main position Quantity % Market Cap. Importance
1/16/26 Issuer sale

Director

31,220 0.2043%
1/16/26 Issuer sale

Chairman

967,492 6.3296%
1/16/26 Issuer sale

Chief Executive Officer

596,303 3.9012%
Change 5-day change 1-year change 3-year change Capi.($)
-4.87%-.--%-36.59%-24.11% 311M
+0.19%+0.30%+25.91%+29.03% 12.58B
-0.77%+1.58%+13.81%+21.94% 6.78B
+0.38%-3.68% - - 5.96B
-0.21%+0.68%+26.01%+22.20% 5.52B
-0.03%-0.74%-18.57%+38.24% 5.06B
+0.76%+1.92%-30.02%-22.08% 3.95B
+0.85%+3.22%+27.35%-3.92% 1.94B
+0.17%-3.97%-20.84%+184.11% 1.67B
-1.95%-0.99%+46.86%-14.47% 1.57B
Average -0.55%+0.55%+3.77%+25.66% 4.53B
Weighted average by Cap. -0.03%+0.66%+10.95%+25.70%

Financials

2023 2024
Net sales 68.18M 59.59M 56M 51.11M 95.92M 6.52B 95.93M 672M 259M 3.33B 256M 250M 10.73B 56.29M 49.2M 46.24M 42.19M 79.19M 5.38B 79.21M 555M 214M 2.75B 211M 207M 8.86B
Net income 20.58M 17.99M 16.91M 15.43M 28.95M 1.97B 28.96M 203M 78.29M 1B 77.3M 75.6M 3.24B 40.9M 35.74M 33.59M 30.66M 57.53M 3.91B 57.54M 403M 156M 2B 154M 150M 6.44B
Net Debt -57.04M -49.84M -46.85M -42.75M -80.24M -5.45B -80.25M -562M -217M -2.78B -214M -210M -8.98B -14.85M -12.98M -12.2M -11.13M -20.89M -1.42B -20.89M -146M -56.48M -725M -55.76M -54.54M -2.34B
Logo Semler Scientific, Inc.
Semler Scientific, Inc. is engaged in developing and marketing technology products and services to healthcare providers to combat chronic diseases. The Company's flagship product, QuantaFlo, which is patented and cleared by the United States Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and the Company is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). QuantaFlo features a sensor clamp that is placed on the toe or finger. A blood flow waveform is instantaneously constructed by its software algorithm. The Company delivers QuantaFlo directly to its customers. The Company also invests in bitcoin and has adopted Bitcoin as its primary treasury asset.
Employees
79
  1. Stock Market
  2. Stocks
  3. SMLR Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!